Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20711762 | 1.00 | PDE4B (0.43) | PDE4BIDO1TDO2USP30PIK3CD | |
| SCHEMBL28385243 | 1.00 | PDE4B (0.43) | PDE4BIDO1TDO2USP30PIK3CD | |
| SCHEMBL20699387 | 0.88 | RXRA (0.39) | PDE4BPIK3CDPDE4APDE4CPDE4D | |
| SCHEMBL20711699 | 0.86 | IDO1 (0.46) | PDE4BIDO1TDO2USP30CCNK | |
| SCHEMBL29606299 | 0.86 | IDO1 (0.46) | PDE4BIDO1TDO2USP30CCNK | |
| SCHEMBL28387149 | 0.85 | PDE4B (0.42) | PDE4BIDO1TDO2USP30PIK3CD | |
| SCHEMBL30161668 | 0.85 | PDE4B (0.42) | PDE4BIDO1TDO2USP30PIK3CD | |
| SCHEMBL20699329 | 0.84 | IDO1 (0.37) | PDE4BIDO1TDO2USP30PIK3CA | |
| SCHEMBL30161698 | 0.84 | IDO1 (0.37) | PDE4BIDO1TDO2USP30PIK3CA | |
| SCHEMBL20711680 | 0.83 | PIK3CD (0.43) | PDE4BPIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032646-B | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | 施万生物制药研发IP有限责任公司 | 2023-01-03 | — | — | CN | disclosed |
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | PDE4B 1261/4885IDO1 566/4885TDO2 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.